(Q34764822)

4 August 2017

1 reference

title

Therapeutic vaccination against chronic viral infections (English)

1 reference

4 August 2017

author name string

Pierre Vandepapelière

series ordinal

1

1 reference

4 August 2017

publication date

1 June 2002

1 reference

Lancet Infectious Diseases

4 August 2017

published in

1 reference

4 August 2017

volume

2

1 reference

4 August 2017

issue

6

1 reference

4 August 2017

page(s)

353-367

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

4 August 2017

1 reference

7 January 2021

Epidemiology of genital human papillomavirus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Herpes simplex virus type 2 in the United States, 1976 to 1994.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Viral Clearance Without Destruction of Infected Cells During Acute HBV Infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Hepatitis B virus immunopathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Influence of T-helper cell subsets and crossregulation in hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

HLA antigens and cervical carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Immunology of papillomavirus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Neutralizing activity of antibodies against the major herpes simplex virus type 1 glycoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

T Cell Responses to Herpes Simplex Viruses in Humans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Studies in subjects with long-term nonprogressive human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Clearance of persistent hepatitis B virus infection in Chinese bone marrow transplant recipients whose donors were anti-hepatitis B core- and anti-hepatitis B surface antibody-positive

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Immunological events in regressing genital warts

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

The efficacy and safety of Skinner herpes simplex vaccine towards modulation of herpes genitalis; report of a prospective double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Herpes simplex virus glycoprotein immunotherapy of recurrent genital herpes: factors influencing efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Immune responses in HIV-exposed seronegatives: have they repelled the virus?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Quantitation of HIV-1-Specific Cytotoxic T Lymphocytes and Plasma Load of Viral RNA

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Prospects for the control of AIDS by immunizing seropositive individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

The basis for HIV immunotherapeutic vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

VACCINE THERAPY IN RECURRENT HERPES SIMPLEX

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Placebo-controlled study with subunit herpes simplex virus vaccine in subjects suffering from frequent herpetic recurrences

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Clinical efficacy of a herpes simplex subunit vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Herpes simplex virus glycoprotein treatment of recurrent genital herpes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Efficacy of recombinant glycoprotein D subunit vaccines on the development of primary, recurrent, and latent genital infections with herpes simplex virus type 2 in guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Immunomodulatory effects of HSV2 glycoprotein D in HSV1 infected mice: implications for immunotherapy of recurrent HSV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Immunotherapy of acute and recurrent herpes simplex virus type 2 infection with an adjuvant-free form of recombinant glycoprotein D-interleukin-2 fusion protein

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus)

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Replication, establishment of latency, and induced reactivation of herpes simplex virus gamma 1 34.5 deletion mutants in rodent models

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Evaluation of a live attenuated recombinant virus RAV 9395 as a herpes simplex virus type 2 vaccine in guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Protection of guinea pigs from primary and recurrent herpes simplex virus (HSV) type 2 cutaneous disease with vaccinia virus recombinants expressing HSV glycoprotein D.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Mucosal immunity and protection after intranasal immunization with recombinant adenovirus expressing herpes simplex virus glycoprotein B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Antibody response and protective capacity of plasmid vaccines expressing three different herpes simplex virus glycoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Hepatitis B vaccine administered to chronic carriers of hepatitis b surface antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Immunotherapy of chronic hepatitis B by anti HBV vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Physical, chemical and immunological stability of CHO-derived hepatitis B surface antigen (HBsAg) particles

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Cross-clade immune responses after immunization with a whole-killed gp120-depleted human immunodeficiency virus type-1 immunogen in incomplete Freund's adjuvant (HIV-1 immunogen, REMUNE) in human immunodeficiency virus type-1 seropositive subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

The effects of an HIV-1 immunogen (Remune) on viral load, CD4 cell counts and HIV-specific immunity in a double-blind, randomized, adjuvant-controlled subset study in HIV infected subjects regardless of concomitant antiviral drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

AIDS vaccine moves into phase 3 trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

A pilot phase II study of the safety and immunogenicity of HIV p17/p24:VLP (p24-VLP) in asymptomatic HIV seropositive subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. Community HIV Research Network Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV inf

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

CD8+ lymphocyte antiviral activity in monkeys immunized with SIV recombinant poxvirus vaccines: potential role in vaccine efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Viremia control following antiretroviral treatment and therapeutic immunizationduring primary SIV251 infection of macaques

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

A therapeutic HIV vaccine using coxsackie-HIV recombinants: a possible new strategy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

A recombinant avipoxvirus HIV-1 vaccine expressing interferon-gamma is safe and immunogenic in macaques

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Induction of HIV-1-specific T-helper responses and type 1 cytokine secretion following therapeutic vaccination of macaques with a recombinant fowlpoxvirus co-expressing interferon-gamma

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

A DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses in rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

A vaccine conjugate of 'ISCAR' immunocarrier and peptide epitopes of the E7 cervical cancer-associated protein of human papillomavirus type 16 elicits specific Th1- and Th2-type responses in immunized mice in the absence of oil-based adjuvants.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Enhanced immunogenicity of a recombinant genital warts vaccine adjuvanted with monophosphoryl lipid A.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Therapeutic potential of protein and adjuvant vaccinations on tumour growth

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumor protection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Ev

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Phase II controlled trial of post-exposure immunization with recombinant gp160 versus antiretroviral therapy in asymptomatic HIV-1-infected adults. VaxSyn Protocol Team

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Solid matrix-antibody-antigen complex can clear viraemia and antigenaemia in persistent duck hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Peptide polymerisation facilitates incorporation into ISCOMs and increases antigen-specific IgG2a production

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

1 reference

7 January 2021

DNA-mediated immunization: prospects for hepatitis B vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

DNA immunization against experimental genital herpes simplex virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Simian immunodeficiency virus DNA vaccine trial in macaques.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

DNA vaccination as anti-human immunodeficiency virus immunotherapy in infected chimpanzees

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Genetic immunization of chimpanzees chronically infected with the hepatitis B virus, using a recombinant retroviral vector encoding the hepatitis B virus core antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Progress in the development of an HIV-1 vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Structured treatment interruptions in antiretroviral management of HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Immune control of HIV-1 after early treatment of acute infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Study protocol for the evaluation of the potential for durable viral suppression after quadruple HAART with or without HIV vaccination: the QUEST study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

Reduction of recurrent HSV disease using imiquimod alone or combined with a glycoprotein vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900289-X

7 January 2021

10.1016/S1473-3099(02)00289-X

Identifiers

DOI

1 reference

4 August 2017

1 reference